AI-driven Drug Discovery for Ulcerative Colitis Treatment

Today's guest is Anne Phelan, Chief Scientific Officer at BenevolentAI. Benevolent is a global leader in applying advanced AI to accelerate pharmaceutical drug discovery, leveraging the latest technologies to uncover new biology, predict novel targets, and develop treatments for some of the world's most complex diseases. Anne joins the program today to give us an insider's view into how her team uses a suite of cutting-edge tools to predict the properties of a drug, as well as its pharmacology and suitability for dosing in humans. This episode is sponsored by BenevolentAI. To learn more about Emerj Media and how to reach the Emerj audience, visit emerj.com/ad1.